BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Repertoire Immune Medicines

1 post

Repertoire Immune Medicines is a clinical-stage biotechnology firm developing medicines that unlock and utilize the massive potential of the human immune system to prevent or treat cancer, as well as autoimmune and viral diseases.

Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery T Cell Receptors

Biotech NewsRepertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors

  • BioTech Health X
  • April 29, 2021
The collaboration between Repertoire and Yale seeks to identify novel antigenic reactivity of T cells in patients with…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Praxis (PRAX) Plunges 37% After Tremor Drug Ulixacaltamide Trial Stopped for Futility
  • Jazz Pharma (JAZZ) Reports $905M R&D Charge, $505M Net Loss in Q2 2025
  • Harrow Health (HROW) Gains Momentum With $59 Cap on Out-of-Pocket Costs
  • uniQure (QURE) Skyrockets 248% on Huntington’s Data
  • Immuneering (IMRX) Reports 86% 9-Month Survival in Pancreatic Cancer
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • September 26, 2025
    Praxis (PRAX) Plunges 37% After Tremor Drug Ulixacaltamide Trial Stopped for Futility
    • September 26, 2025
    Jazz Pharma (JAZZ) Reports $905M R&D Charge, $505M Net Loss in Q2 2025
    • September 26, 2025
    Harrow Health (HROW) Gains Momentum With $59 Cap on Out-of-Pocket Costs
    • September 26, 2025
    uniQure (QURE) Skyrockets 248% on Huntington’s Data
    • September 25, 2025
    Immuneering (IMRX) Reports 86% 9-Month Survival in Pancreatic Cancer
Recent Posts
  • Qualigen Therapeutics (QLGN) Secures $41M Faraday Future Deal
    • September 25, 2025
  • BriaCell (BCTX) Raises $13.8M to Advance Cancer Immunotherapy Pipeline
    • September 25, 2025
  • PepGen (PEPG) Soars 96.8% After Breakthrough DM1 Results
    • September 25, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (1)
  • Biotech News (415)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top